The Once-a-Month GLP-1: Meet Berobenatide
Pfizer is late to the GLP-1 party. Novo Nordisk and Eli Lilly have been running it for years, and Pfizer's own attempts to build one of these drugs in-house both failed. So Pfizer did what big drug companies do when they are late: it bought its way in.
In November 2025, Pfizer bought a small biotech called Metsera for about $7 billion, outbidding Novo Nordisk in the process, and the prize in that deal was a drug called berobenatide. It is Pfizer's GLP-1, and if it works the way Pfizer hopes, it will be the first one you only inject once a month.
What is Berobenatide?
Berobenatide is a GLP-1 receptor agonist, the same family as Ozempic, Wegovy, Mounjaro, and Zepbound. It works the same basic way: it mimics a gut hormone, slows how fast your stomach empties, curbs appetite, and helps your body release insulin when blood sugar rises.
What is different is the engineering. Most GLP-1s are built on the human GLP-1 hormone. Berobenatide is built on exendin-4, a peptide first found in Gila monster venom, the same starting point as the older diabetes drug exenatide.
And it is tuned to hit the receptor in a lopsided way, favoring the signals tied to appetite and blood sugar over the ones tied to nausea and the receptor going quiet over time. Whether that tuning means fewer side effects in real people is still unproven. It is the design goal, not a result.
The other difference is the one that matters most to anyone who takes these drugs: how long it lasts. The plan is weekly injections for the first 12 weeks while the dose is worked up, then a single monthly shot for maintenance. Pfizer calls it a potential first-in-class monthly GLP-1. If it reaches the market on that schedule, it would be the first in the class you take twelve times a year instead of fifty-two.
Who is developing it, and how Pfizer got here
The drug started at Metsera, where it was called MET-097i. Pfizer completed the acquisition on November 13, 2025, after a bidding war with Novo Nordisk. Inside Pfizer, it goes by PF-08653944, or PF'3944. Pfizer needed the deal because its own GLP-1 program kept falling apart.
Its oral GLP-1, danuglipron, was dropped in December 2023 after liver enzyme problems showed up in trials, and an earlier candidate, lotiglipron, was dropped in June 2023. This is not Pfizer's first try at the class. It is the one it bought after the homegrown versions failed, and the company has since cut other overlapping obesity programs from the same deal to put everything behind it.
Pfizer plans more than 20 obesity trials in 2026, including ten Phase 3 studies for berobenatide alone.
Approval status: not approved, and not close
Berobenatide is investigational. It is not approved anywhere, and you cannot get it outside a clinical trial. The Phase 3 program, called VESPER, started in December 2025. The main weight-management trial (VESPER-4, about 3,578 people) and the diabetes trial (VESPER-5, about 1,078 people) have finished enrolling, with results expected in the second half of 2027.
The pivotal monthly-dosing trial (VESPER-6, about 954 people) is still recruiting, alongside trials for sleep apnea, for people switching from semaglutide or tirzepatide, and in China and Japan. Pfizer is targeting first approvals beginning in 2028.
Nothing below comes from a finished Phase 3 trial. All of it is mid-stage data, presented at a conference and in company announcements, not yet published in a peer-reviewed journal.
What the trials have shown so far
The Phase 2b results were presented at the American Diabetes Association meeting on June 6, 2026. In the main weekly study (VESPER-1, 239 adults with obesity), weight loss versus placebo at 28 weeks ran 8.1% to 14.1% across the four doses, topping out at 1.2 mg weekly.
An extension reached 15.9% at 32 weeks on 2.4 mg weekly, with no plateau yet, though that number is not adjusted against placebo. In the diabetes study (VESPER-2), 1.6 mg weekly cut HbA1c by 2.2% at 28 weeks. And in the monthly study (VESPER-3), switching to monthly maintenance produced 12.3% placebo-adjusted weight loss at 28 weeks.
On tolerability, Pfizer says gut side effects were unusually low despite fast dose increases, and only 2 of 239 people in VESPER-1 stopped because of side effects. The counterweight is that 10% of people on the planned late-stage monthly regimen stopped because of adverse events.
Both can be true at once, and Phase 3 is where the real picture comes out.
How it compares to the drugs you already know
The same: same receptor, same basic mechanism, same weekly shots during the ramp-up, and the same family of side effects to expect.
The difference: first, the monthly schedule, which no approved GLP-1 offers. Second, the biased signaling, a real design difference with an unproven benefit. Third, it is a single GLP-1 agonist, not a dual like tirzepatide or a triple like the experimental retatrutide, so it has no structural path to beat them on pure weight loss.
Tirzepatide routinely delivers 15 to 20% over a year in late-stage trials, and berobenatide's mid-stage numbers sit in the same range or a little below. Its edge, if it has one, is convenience, not potency.
Fourth, there is no pill version, while the Wegovy pill is already on sale in the US. And fifth, there is no cardiovascular outcomes data yet, the long-term heart evidence semaglutide and tirzepatide already carry.
Pfizer is also testing it paired with an amylin drug in a Phase 2 trial, the same playbook other companies use.
The bottom line
Berobenatide is the new GLP-1 to watch if you care about how often you inject, rather than how much more weight the next drug squeezes out. A monthly shot would change the arithmetic of staying on treatment: weekly shots are easy to miss, and missed shots are how weight comes back.
But it is still a Phase 3 drug with no finished late-stage results, no peer-reviewed publication, no heart data, and no approval before 2028 at the earliest. It is also not for sale anywhere. Anything labeled berobenatide online is unregulated research material, not a medicine, with no quality control and no doctor involved.
Pfizer is finally in the game. Whether it wins anything with this drug depends on the VESPER results in 2027, and on whether a monthly shot is enough to matter when the competition is already selling drugs that work a little better, every single week.
I'm all for this, because - hopefully - the more GLP-1 medications there are, the lower the costs might eventually be.
Comments